Quest for the right Drug
לוריוון LORIVAN (LORAZEPAM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 Posology and method of administration Lorivan tablets are for oral administration only. Treatment to be given under close medical supervision. Dosage and duration of therapy should be individualised. The lowest effective dose should be prescribed for the shortest time possible. The risk of withdrawal and rebound phenomena is greater after abrupt discontinuation; therefore, the drug should be discontinued gradually for all patients (see section 4.4). Generally, the duration of treatment varies from a few days to 4 weeks including the tapering off process. Chronic use is not recommended (little is known of the long term safety and efficacy; potential for dependence – see section 4.4). Extension of the treatment period should not take place without re- evaluation of the need for continued therapy. Increases in the dosage of lorazepam should be made gradually to help avoid adverse effects. The evening dose should be increased before the daytime doses. When treatment is started, the patient should be informed that: • treatment will be of limited duration • the dosage will be progressively decreased • there is a possibility of rebound phenomena Dosage: Adults: 1-4 mg daily in divided doses. Elderly and debilitated patients: Elderly and debilitated patients may respond to lower doses and half the normal adult dose or less may be sufficient. This initial dose should be adjusted as needed and tolerated. Children (under the age of 13 years): Lorazepam is not intended for the treatment of children under the age of 13 years. Patients with Renal or Hepatic impairment: Lower doses may be sufficient in patients with impaired renal function or mild to moderate hepatic insufficiency (see section 4.4 special warnings and precautions for use). Use in patients with severe hepatic insufficiency is contraindicated (see section 4.3 Contraindications).
שימוש לפי פנקס קופ''ח כללית 1994
Anxiety & tension
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף
